Galmed Pharmaceuticals Ltd (NAS:GLMD)
$ 2.87 -0.07 (-2.38%) Market Cap: 4.75 Mil Enterprise Value: -7.73 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 36/100

Q3 2020 Galmed Pharmaceuticals Ltd Earnings Call Transcript

Nov 12, 2020 / 01:30PM GMT
Release Date Price: $570.6 (-5.65%)
Operator

Good day and welcome to the Galmed conference call to discuss financial results for the third quarter of 2020. Today's conference is being recorded.

Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events.

These statements are based on the beliefs and expectations of management as of today and actual results, trends, timelines and projections relating to our financial position and projected development programs and pipeline could differ materially. In particular, there is significant uncertainty about the duration and severity of the COVID-19 pandemic and its impact on Galmed's business and operations.

We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under the heading Risk Factors described in our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot